Welcome to our dedicated page for Astria Therapeutics SEC filings (Ticker: ATXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Astria Therapeutics, Inc. (ATXS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq‑listed biopharmaceutical issuer. Astria’s filings, including Forms 8‑K, 10‑K, and 10‑Q when available, document key information about its clinical‑stage programs in hereditary angioedema and atopic dermatitis, as well as its material agreements and corporate transactions.
Recent Form 8‑K filings illustrate how Astria uses SEC reports to communicate significant events. One 8‑K describes an Agreement and Plan of Merger with BioCryst Pharmaceuticals, Inc., under which a BioCryst subsidiary will merge with and into Astria, with Astria surviving as a wholly owned subsidiary if closing conditions are met. The filing outlines the cash and stock consideration, treatment of common stock, preferred stock, options, and warrants, and notes that Astria common stock is expected to be delisted from Nasdaq and deregistered under the Exchange Act if the merger is consummated.
Another 8‑K details a license agreement with Kaken Pharmaceutical Co., Ltd., granting Kaken exclusive rights to develop, package, and commercialize navenibart in Japan for prevention of hereditary angioedema attacks, including financial terms such as an upfront payment, potential milestones, and tiered royalties, as well as Kaken’s obligations to support Phase 3 development and handle regulatory submissions in Japan. Additional 8‑K filings cover quarterly financial results and other corporate updates.
On Stock Titan, these SEC filings are paired with AI‑powered summaries that explain the core points of lengthy documents, helping readers quickly understand merger terms, licensing economics, clinical development commitments, and capital considerations. Real‑time updates from EDGAR ensure new Astria filings, including future 10‑K annual reports, 10‑Q quarterly reports, and any Form 4 insider transaction reports, are surfaced promptly, while AI‑generated highlights make dense regulatory language more accessible for investors researching ATXS.
Astria Therapeutics, Inc.’s Chief Business Officer Andrea Matthews reported the cancellation of several stock option awards in connection with the company’s merger with BioCryst Pharmaceuticals, Inc. On January 23, 2026, Axel Merger Sub, Inc. merged into Astria, making Astria a wholly owned subsidiary of BioCryst. At the merger’s effective time, each Astria stock option with an exercise price below $13.00 became fully vested and exercisable, then was canceled for a cash payment based on the spread between $13.00 and the option’s exercise price.
Matthews reported three such stock option grants being disposed of: options to buy 32,812 shares at $6.51, 20,000 shares at $10.82, and 262,500 shares at $6.41. Each grant was reported with a transaction code “D” and a post-transaction balance of zero derivative securities, indicating these options were fully cashed out and no longer held following the merger-related payout.
Astria Therapeutics director Anthony Gregg Lapointe reported the cash cancellation of his stock options in connection with the acquisition of Astria Therapeutics, Inc. by BioCryst Pharmaceuticals, Inc. On January 23, 2026, Axel Merger Sub, Inc. merged into Astria, making Astria a wholly owned subsidiary of BioCryst.
At the merger’s effective time, each Astria stock option with an exercise price below $13.00 became fully vested and exercisable, then was canceled in exchange for a cash payment based on the number of underlying shares and the difference between $13.00 and the option’s exercise price. Reported tranches include stock options to purchase 16,666 shares at $12.24, 8,333 shares at $3.00, 14,100 shares at $11.35, 14,100 shares at $9.18, and 26,550 shares at $5.79, all reduced to zero following the transactions. Options with exercise prices at or above $13.00 were canceled for no consideration and are not reported here.
Astria Therapeutics Chief Commercial Officer Andrew Komjathy filed a Form 4 reflecting automatic changes to his equity interests following the completion of a merger in which Astria became a wholly owned subsidiary of BioCryst Pharmaceuticals. At the merger's effective time, each share of Astria common stock (other than excluded or dissenting shares) was converted into the right to receive 0.59 of a BioCryst common share plus $8.55 in cash per share, before taxes and any cash in lieu of fractional shares.
The filing shows small amounts of Astria common stock disposed of, including shares held directly, in a Uniform Transfers to Minors Act brokerage account for a minor child, and by an adult child; the reporting person disclaims beneficial ownership of the child-held shares except for any indirect pecuniary interest. In addition, stock options covering 55,000 and 225,000 Astria shares with exercise prices of $6.51 and $6.41 were treated as in-the-money options, became fully vested, and were canceled at closing in exchange for cash based on a $13.00 reference price.
Astria Therapeutics director reports option cancellation in BioCryst merger
Director Michael D. Kishbauch filed a Form 4 for Astria Therapeutics, Inc. showing the disposition of several stock option awards on January 23, 2026, the closing date of the company’s merger with BioCryst Pharmaceuticals. Multiple “Stock Option (Right to Buy)” positions with exercise prices below $13.00 were fully vested at the merger’s effective time and then canceled, with each such in-the-money option exchanged for a cash payment based on the difference between $13.00 and its exercise price, multiplied by the number of underlying shares. The reported option positions each show a disposition code “D” and a resulting balance of zero derivative securities owned directly following the transactions.
Astria Therapeutics Chief Legal Officer Benjamin Harshbarger reported the cash cancelation of his stock options in connection with Astria’s merger with BioCryst Pharmaceuticals. On January 23, 2026, Axel Merger Sub, Inc. merged with Astria, making Astria a wholly owned subsidiary of BioCryst. At the effective time of the merger, each Astria stock option with an exercise price of less than $13.00 became fully vested and exercisable and was canceled in exchange for a cash payment based on the number of underlying shares and the excess of $13.00 over the option’s exercise price.
For Harshbarger, this Form 4 shows the disposition of three stock option grants: 33,333 options with a $12.96 exercise price, 55,000 options at $6.51, and 262,500 options at $6.41, all reported as derivative securities disposed of, leaving 0 such options beneficially owned after the transactions. Options with exercise prices at or above $13.00 were canceled for no consideration and are noted as exempt from Section 16 reporting.
Astria Therapeutics director Hugh M. Cole reported the cash cancellation of his stock options in connection with the company’s merger into BioCryst Pharmaceuticals. On January 23, 2026, multiple stock option grants to buy Astria common stock, with exercise prices of $12.24, $3.00, $11.35, $9.18 and $5.79, were disposed of, leaving him with 0 derivative securities beneficially owned after the transactions.
Under the merger agreement among Astria, BioCryst and Axel Merger Sub, each option with an exercise price below $13.00 became fully vested and exercisable at the merger’s effective time and was canceled in exchange for a cash payment based on the difference between $13.00 and the option’s exercise price, multiplied by the number of underlying shares. Options with exercise prices at or above $13.00 were canceled for no consideration and are not included in this report.
Astria Therapeutics, Inc. Chief Financial Officer Noah Clauser reported the cash cancellation of stock options in connection with the company’s merger with BioCryst Pharmaceuticals, Inc. On January 23, 2026, Axel Merger Sub, Inc. merged with and into Astria, leaving Astria as a wholly owned subsidiary of BioCryst.
At the effective time of the merger, each Astria stock option with an exercise price below $13.00 became fully vested and exercisable and was then canceled in exchange for a cash payment. The cash amount for each such option equals the number of underlying common shares multiplied by the difference between $13.00 and the option’s exercise price. Clauser’s Form 4 reports dispositions of 55,000 and 262,500 stock options, both held directly, leaving no derivative securities of these types after the transactions. Options with exercise prices at or above $13.00 were canceled for no consideration and are not reported.
Astria Therapeutics director Fred Callori reported the cancellation of several stock options in connection with Astria’s merger with BioCryst Pharmaceuticals. On January 23, 2026, BioCryst’s wholly owned subsidiary merged into Astria, leaving Astria as a wholly owned BioCryst subsidiary. At the merger’s effective time, each Astria stock option with an exercise price below $13.00 became fully vested and exercisable, then was canceled in exchange for cash equal to the number of option shares multiplied by the difference between $13.00 and the option’s exercise price. The Form 4 lists multiple such stock options, with exercise prices ranging from $3.00 to $12.24, all ending with zero derivative securities beneficially owned after the transactions. Options with exercise prices at or above $13.00 were canceled for no consideration and are not reported here.
Astria Therapeutics, Inc. director Joanne T. Beck reported the cash cancellation of multiple stock option awards in connection with the company’s merger into BioCryst Pharmaceuticals. On January 23, 2026, a wholly owned BioCryst subsidiary merged with Astria, making Astria a wholly owned BioCryst subsidiary. At the merger’s effective time, each Astria stock option with an exercise price below $13.00 became fully vested and exercisable, then was canceled in exchange for a cash payment based on the number of underlying shares and the difference between $13.00 and the option’s exercise price. The filing lists several such stock option cancellations, including awards covering 16,666, 8,333, 14,100, 14,100, and 26,550 shares of common stock. Options with exercise prices at or above $13.00 were canceled for no consideration and are not reported in this form.
Astria Therapeutics director Kenneth Bate reported the disposition of multiple stock option awards in connection with the acquisition of Astria Therapeutics, Inc. by BioCryst Pharmaceuticals, Inc. on January 23, 2026. The Form 4 shows several stock options (rights to buy common stock) with various exercise prices being disposed of, leaving 0 derivative securities beneficially owned after the transactions.
According to the footnotes, at the effective time of the merger each Astria stock option with an exercise price below $13.00 became fully vested and exercisable and was then canceled in exchange for a cash payment equal to the number of underlying shares multiplied by the excess of $13.00 over the option’s exercise price. Options with exercise prices at or above $13.00 were canceled for no consideration and are not listed. The option numbers reflect a prior 1‑for‑6 reverse stock split completed on August 19, 2021.